 Kennon Heard
Concepts (635)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acetaminophen | 39 | 2023 | 241 | 8.700 |
Why?
| | Chemical and Drug Induced Liver Injury | 15 | 2023 | 125 | 4.920 |
Why?
| | Analgesics, Non-Narcotic | 20 | 2022 | 117 | 4.510 |
Why?
| | Drug Overdose | 30 | 2022 | 292 | 4.250 |
Why?
| | Emergency Service, Hospital | 40 | 2023 | 1815 | 3.720 |
Why?
| | Poisoning | 17 | 2017 | 110 | 3.140 |
Why?
| | Poison Control Centers | 11 | 2023 | 84 | 2.740 |
Why?
| | Alanine Transaminase | 14 | 2023 | 140 | 2.690 |
Why?
| | Acetylcysteine | 11 | 2023 | 141 | 2.670 |
Why?
| | Cannabis | 9 | 2020 | 382 | 2.570 |
Why?
| | Cocaine | 10 | 2011 | 153 | 2.520 |
Why?
| | Prescription Drugs | 9 | 2018 | 116 | 2.290 |
Why?
| | Analgesics, Opioid | 8 | 2023 | 770 | 1.720 |
Why?
| | Antidotes | 9 | 2020 | 135 | 1.570 |
Why?
| | Legislation, Drug | 5 | 2017 | 78 | 1.530 |
Why?
| | Cysteine | 4 | 2017 | 172 | 1.440 |
Why?
| | Antipsychotic Agents | 7 | 2019 | 183 | 1.390 |
Why?
| | Marijuana Use | 4 | 2021 | 166 | 1.310 |
Why?
| | Male | 101 | 2022 | 55112 | 1.300 |
Why?
| | Humans | 152 | 2023 | 113531 | 1.210 |
Why?
| | Medication Errors | 5 | 2015 | 88 | 1.210 |
Why?
| | Female | 95 | 2022 | 59115 | 1.140 |
Why?
| | Pain | 9 | 2020 | 699 | 1.140 |
Why?
| | Cocaine-Related Disorders | 5 | 2011 | 108 | 1.130 |
Why?
| | Adult | 73 | 2022 | 30245 | 1.130 |
Why?
| | Emergency Medicine | 6 | 2019 | 222 | 1.120 |
Why?
| | Toxicology | 4 | 2021 | 35 | 1.110 |
Why?
| | Drug Packaging | 2 | 2017 | 42 | 1.090 |
Why?
| | Medication Reconciliation | 2 | 2016 | 25 | 1.000 |
Why?
| | Dose-Response Relationship, Drug | 16 | 2017 | 1822 | 0.990 |
Why?
| | Antidepressive Agents, Tricyclic | 5 | 2014 | 29 | 0.920 |
Why?
| | Spider Bites | 5 | 2019 | 9 | 0.920 |
Why?
| | Middle Aged | 54 | 2022 | 26552 | 0.920 |
Why?
| | Diphenhydramine | 4 | 2023 | 30 | 0.910 |
Why?
| | Young Adult | 30 | 2020 | 10400 | 0.900 |
Why?
| | Akathisia, Drug-Induced | 2 | 2020 | 6 | 0.890 |
Why?
| | Antivenins | 5 | 2019 | 56 | 0.880 |
Why?
| | Thiazoles | 4 | 2009 | 109 | 0.880 |
Why?
| | Prescription Drug Monitoring Programs | 1 | 2023 | 13 | 0.860 |
Why?
| | Spider Venoms | 4 | 2019 | 11 | 0.850 |
Why?
| | Heart Arrest | 8 | 2018 | 293 | 0.840 |
Why?
| | Referral and Consultation | 2 | 2020 | 632 | 0.830 |
Why?
| | Benzodiazepines | 5 | 2011 | 114 | 0.820 |
Why?
| | Decision Support Systems, Clinical | 2 | 2023 | 176 | 0.820 |
Why?
| | Muscarinic Antagonists | 3 | 2023 | 25 | 0.820 |
Why?
| | Seizures | 6 | 2011 | 335 | 0.820 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 297 | 0.780 |
Why?
| | Piperazines | 4 | 2009 | 309 | 0.770 |
Why?
| | Physostigmine | 2 | 2020 | 10 | 0.760 |
Why?
| | Emergency Treatment | 4 | 2015 | 113 | 0.760 |
Why?
| | Lorazepam | 2 | 2020 | 23 | 0.760 |
Why?
| | Delirium | 2 | 2020 | 67 | 0.760 |
Why?
| | Black Widow Spider | 4 | 2019 | 9 | 0.750 |
Why?
| | Medical History Taking | 3 | 2018 | 115 | 0.740 |
Why?
| | Dopamine Uptake Inhibitors | 3 | 2011 | 54 | 0.740 |
Why?
| | Suicide, Attempted | 5 | 2012 | 317 | 0.720 |
Why?
| | Retrospective Studies | 30 | 2022 | 12504 | 0.710 |
Why?
| | Abdominal Pain | 2 | 2019 | 133 | 0.710 |
Why?
| | Anti-Arrhythmia Agents | 4 | 2014 | 106 | 0.700 |
Why?
| | Hospitals, Pediatric | 4 | 2018 | 480 | 0.690 |
Why?
| | Back Pain | 1 | 2020 | 44 | 0.680 |
Why?
| | Vasoconstrictor Agents | 4 | 2009 | 113 | 0.680 |
Why?
| | Buprenorphine | 2 | 2020 | 133 | 0.680 |
Why?
| | Patient Handoff | 1 | 2020 | 27 | 0.660 |
Why?
| | Free Radical Scavengers | 2 | 2011 | 78 | 0.660 |
Why?
| | Ketorolac | 1 | 2019 | 17 | 0.640 |
Why?
| | Haloperidol | 1 | 2019 | 35 | 0.640 |
Why?
| | Prospective Studies | 18 | 2023 | 6189 | 0.640 |
Why?
| | Social Work | 1 | 2020 | 74 | 0.630 |
Why?
| | Colorado | 15 | 2021 | 4061 | 0.630 |
Why?
| | Substance-Related Disorders | 5 | 2012 | 931 | 0.620 |
Why?
| | Pharmacoepidemiology | 1 | 2018 | 20 | 0.620 |
Why?
| | Child | 28 | 2023 | 18340 | 0.620 |
Why?
| | Tertiary Care Centers | 3 | 2017 | 127 | 0.610 |
Why?
| | Gastric Lavage | 3 | 2009 | 9 | 0.600 |
Why?
| | Vomiting | 6 | 2019 | 120 | 0.600 |
Why?
| | Immunoglobulin Fab Fragments | 4 | 2019 | 69 | 0.590 |
Why?
| | Cannabinoids | 3 | 2017 | 115 | 0.580 |
Why?
| | Hypotension | 2 | 2022 | 115 | 0.580 |
Why?
| | Drug Storage | 2 | 2017 | 57 | 0.570 |
Why?
| | Medical Marijuana | 2 | 2019 | 97 | 0.560 |
Why?
| | Pulmonary Embolism | 3 | 2021 | 181 | 0.560 |
Why?
| | Accidents, Home | 1 | 2017 | 27 | 0.560 |
Why?
| | Plant Preparations | 2 | 2015 | 23 | 0.550 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2007 | 79 | 0.540 |
Why?
| | Calcium Gluconate | 1 | 2016 | 4 | 0.540 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2016 | 44 | 0.530 |
Why?
| | Mobile Applications | 1 | 2018 | 140 | 0.530 |
Why?
| | Hypocalcemia | 1 | 2016 | 30 | 0.520 |
Why?
| | Practice Patterns, Physicians' | 3 | 2023 | 1176 | 0.520 |
Why?
| | Health Records, Personal | 1 | 2016 | 24 | 0.520 |
Why?
| | Treatment Outcome | 18 | 2020 | 9006 | 0.520 |
Why?
| | Liver | 6 | 2022 | 1630 | 0.510 |
Why?
| | Blood Proteins | 1 | 2017 | 217 | 0.510 |
Why?
| | Nonprescription Drugs | 4 | 2016 | 68 | 0.510 |
Why?
| | Antidepressive Agents | 2 | 2012 | 195 | 0.510 |
Why?
| | Child, Preschool | 13 | 2018 | 9093 | 0.510 |
Why?
| | Fat Emulsions, Intravenous | 2 | 2014 | 27 | 0.500 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 5 | 2023 | 239 | 0.490 |
Why?
| | Infant | 12 | 2018 | 7922 | 0.490 |
Why?
| | Prescription Drug Misuse | 1 | 2015 | 38 | 0.490 |
Why?
| | Emergency Medical Services | 4 | 2016 | 586 | 0.490 |
Why?
| | Electrocardiography | 5 | 2013 | 558 | 0.480 |
Why?
| | Adolescent | 27 | 2020 | 17724 | 0.470 |
Why?
| | Electronic Health Records | 3 | 2023 | 801 | 0.460 |
Why?
| | Asymptomatic Diseases | 2 | 2013 | 75 | 0.450 |
Why?
| | Crime | 2 | 2011 | 56 | 0.450 |
Why?
| | Observer Variation | 3 | 2010 | 298 | 0.440 |
Why?
| | Double-Blind Method | 7 | 2020 | 1643 | 0.440 |
Why?
| | Arrhythmias, Cardiac | 3 | 2022 | 281 | 0.440 |
Why?
| | Aged | 27 | 2019 | 18944 | 0.440 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 24 | 0.430 |
Why?
| | Energy Drinks | 1 | 2013 | 4 | 0.430 |
Why?
| | Performance-Enhancing Substances | 1 | 2013 | 7 | 0.430 |
Why?
| | Accidents | 1 | 2013 | 39 | 0.420 |
Why?
| | Bradycardia | 1 | 2013 | 47 | 0.420 |
Why?
| | Dronabinol | 4 | 2021 | 118 | 0.420 |
Why?
| | Diet Surveys | 1 | 2013 | 78 | 0.420 |
Why?
| | Poisons | 2 | 2023 | 21 | 0.420 |
Why?
| | Plasmapheresis | 1 | 2013 | 21 | 0.420 |
Why?
| | Amphotericin B | 1 | 2013 | 27 | 0.420 |
Why?
| | Hematemesis | 1 | 2012 | 3 | 0.420 |
Why?
| | Disease Models, Animal | 9 | 2011 | 3470 | 0.420 |
Why?
| | Foreign Bodies | 2 | 2011 | 93 | 0.420 |
Why?
| | Phytotherapy | 1 | 2013 | 66 | 0.410 |
Why?
| | beta-Alanine | 1 | 2012 | 17 | 0.410 |
Why?
| | Aspartate Aminotransferases | 3 | 2010 | 84 | 0.410 |
Why?
| | Stomach Diseases | 1 | 2012 | 19 | 0.410 |
Why?
| | Ethers | 1 | 2012 | 16 | 0.410 |
Why?
| | Sulfonylurea Compounds | 2 | 2010 | 44 | 0.410 |
Why?
| | Alcohol Drinking | 4 | 2012 | 651 | 0.410 |
Why?
| | Antithrombins | 1 | 2012 | 49 | 0.400 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 2077 | 0.400 |
Why?
| | Opioid-Related Disorders | 2 | 2020 | 412 | 0.400 |
Why?
| | Citalopram | 1 | 2012 | 28 | 0.400 |
Why?
| | Drug Administration Schedule | 5 | 2014 | 712 | 0.400 |
Why?
| | Liver Function Tests | 7 | 2020 | 104 | 0.400 |
Why?
| | Antifungal Agents | 1 | 2013 | 125 | 0.390 |
Why?
| | C-Peptide | 2 | 2010 | 138 | 0.390 |
Why?
| | Aged, 80 and over | 15 | 2018 | 6296 | 0.390 |
Why?
| | Burns | 2 | 2015 | 232 | 0.390 |
Why?
| | Propafenone | 1 | 2011 | 2 | 0.390 |
Why?
| | Thiophenes | 1 | 2012 | 108 | 0.390 |
Why?
| | Benzimidazoles | 1 | 2012 | 137 | 0.380 |
Why?
| | Firesetting Behavior | 1 | 2011 | 1 | 0.380 |
Why?
| | Infusions, Intravenous | 6 | 2013 | 368 | 0.380 |
Why?
| | Charcoal | 4 | 2006 | 23 | 0.380 |
Why?
| | Clinical Enzyme Tests | 2 | 2013 | 11 | 0.380 |
Why?
| | Temperance | 2 | 2010 | 13 | 0.370 |
Why?
| | Administration, Intravenous | 4 | 2016 | 122 | 0.370 |
Why?
| | Chemical and Drug Induced Liver Injury, Chronic | 1 | 2011 | 9 | 0.370 |
Why?
| | Brain Edema | 1 | 2011 | 52 | 0.360 |
Why?
| | Evidence-Based Medicine | 4 | 2023 | 662 | 0.360 |
Why?
| | Self-Injurious Behavior | 1 | 2012 | 114 | 0.360 |
Why?
| | Cholinergic Antagonists | 1 | 2011 | 27 | 0.360 |
Why?
| | Amitriptyline | 2 | 2001 | 20 | 0.360 |
Why?
| | Immunologic Factors | 2 | 2019 | 211 | 0.360 |
Why?
| | Time Factors | 12 | 2020 | 6032 | 0.360 |
Why?
| | Blood Chemical Analysis | 3 | 2021 | 90 | 0.360 |
Why?
| | Liver Failure | 1 | 2011 | 72 | 0.360 |
Why?
| | Population Surveillance | 1 | 2013 | 385 | 0.350 |
Why?
| | Tachycardia, Ventricular | 1 | 2012 | 153 | 0.350 |
Why?
| | United States | 17 | 2023 | 12137 | 0.350 |
Why?
| | Cross-Sectional Studies | 9 | 2020 | 4400 | 0.350 |
Why?
| | Anaphylaxis | 2 | 2012 | 144 | 0.350 |
Why?
| | Surveys and Questionnaires | 4 | 2018 | 4593 | 0.350 |
Why?
| | Hydrofluoric Acid | 2 | 2016 | 8 | 0.350 |
Why?
| | Pharmaceutical Vehicles | 1 | 2010 | 11 | 0.340 |
Why?
| | Propylene Glycol | 1 | 2010 | 9 | 0.340 |
Why?
| | Risk Factors | 9 | 2017 | 8606 | 0.340 |
Why?
| | Barium | 1 | 2009 | 24 | 0.340 |
Why?
| | Acidosis, Lactic | 1 | 2010 | 27 | 0.340 |
Why?
| | Warfarin | 1 | 2010 | 136 | 0.340 |
Why?
| | Liver Diseases, Alcoholic | 2 | 2007 | 81 | 0.330 |
Why?
| | Explosive Agents | 1 | 2009 | 9 | 0.330 |
Why?
| | Hypokalemia | 1 | 2009 | 23 | 0.330 |
Why?
| | Length of Stay | 3 | 2020 | 963 | 0.330 |
Why?
| | Imines | 2 | 2022 | 7 | 0.330 |
Why?
| | Iatrogenic Disease | 1 | 2010 | 47 | 0.330 |
Why?
| | Risk Assessment | 8 | 2017 | 2953 | 0.330 |
Why?
| | Emetics | 2 | 2006 | 7 | 0.330 |
Why?
| | Deception | 1 | 2009 | 16 | 0.330 |
Why?
| | Random Allocation | 3 | 2007 | 326 | 0.320 |
Why?
| | Benzoquinones | 2 | 2022 | 44 | 0.320 |
Why?
| | Oximetry | 1 | 2009 | 80 | 0.320 |
Why?
| | Odds Ratio | 7 | 2017 | 953 | 0.310 |
Why?
| | Hypothermia, Induced | 1 | 2009 | 65 | 0.310 |
Why?
| | Point-of-Care Systems | 1 | 2010 | 130 | 0.310 |
Why?
| | Animals | 20 | 2019 | 31162 | 0.300 |
Why?
| | Intellectual Disability | 1 | 2009 | 127 | 0.300 |
Why?
| | Hypoglycemia | 2 | 2010 | 386 | 0.300 |
Why?
| | Eyelashes | 1 | 2008 | 3 | 0.300 |
Why?
| | Cyanoacrylates | 1 | 2008 | 4 | 0.300 |
Why?
| | Reference Values | 4 | 2017 | 735 | 0.300 |
Why?
| | Adhesives | 1 | 2008 | 11 | 0.300 |
Why?
| | Detergents | 1 | 2008 | 40 | 0.290 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 557 | 0.290 |
Why?
| | Cardiovascular System | 1 | 2009 | 124 | 0.290 |
Why?
| | Publishing | 1 | 2009 | 123 | 0.290 |
Why?
| | Brugada Syndrome | 1 | 2007 | 9 | 0.280 |
Why?
| | Clinical Laboratory Techniques | 1 | 2008 | 86 | 0.280 |
Why?
| | Diazepam | 1 | 2007 | 26 | 0.280 |
Why?
| | Niacin | 1 | 2007 | 18 | 0.280 |
Why?
| | Pediatrics | 1 | 2015 | 981 | 0.280 |
Why?
| | Mice, Inbred Strains | 4 | 2009 | 394 | 0.280 |
Why?
| | Vitamin B Complex | 1 | 2007 | 38 | 0.270 |
Why?
| | Specimen Handling | 1 | 2008 | 152 | 0.270 |
Why?
| | Thromboembolism | 1 | 2007 | 92 | 0.270 |
Why?
| | Analgesics | 4 | 2017 | 156 | 0.270 |
Why?
| | Brain Infarction | 1 | 2006 | 22 | 0.270 |
Why?
| | Anticoagulants | 1 | 2010 | 548 | 0.270 |
Why?
| | Self Report | 4 | 2021 | 696 | 0.260 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2012 | 1205 | 0.260 |
Why?
| | Age Factors | 7 | 2017 | 2875 | 0.260 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2006 | 24 | 0.260 |
Why?
| | Nausea | 4 | 2014 | 96 | 0.260 |
Why?
| | Intention | 1 | 2007 | 143 | 0.260 |
Why?
| | Decontamination | 1 | 2006 | 23 | 0.260 |
Why?
| | Epilepsy | 2 | 2020 | 278 | 0.260 |
Why?
| | Databases, Factual | 1 | 2010 | 1127 | 0.260 |
Why?
| | Venous Thrombosis | 1 | 2007 | 142 | 0.250 |
Why?
| | Amiodarone | 1 | 2005 | 23 | 0.250 |
Why?
| | Acute Kidney Injury | 1 | 2012 | 676 | 0.250 |
Why?
| | Biomarkers | 7 | 2021 | 3389 | 0.250 |
Why?
| | Eating | 4 | 2017 | 340 | 0.250 |
Why?
| | Vasospasm, Intracranial | 1 | 2005 | 17 | 0.250 |
Why?
| | Education, Medical | 2 | 2021 | 214 | 0.250 |
Why?
| | Hypoglycemic Agents | 2 | 2010 | 1006 | 0.240 |
Why?
| | Diagnostic Imaging | 1 | 2007 | 278 | 0.240 |
Why?
| | Sodium Nitrite | 1 | 2005 | 37 | 0.240 |
Why?
| | Reproducibility of Results | 5 | 2011 | 2752 | 0.240 |
Why?
| | Drug Utilization | 5 | 2014 | 164 | 0.240 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2005 | 59 | 0.240 |
Why?
| | Coma | 2 | 2006 | 30 | 0.240 |
Why?
| | Insulin | 3 | 2019 | 2076 | 0.230 |
Why?
| | Case-Control Studies | 4 | 2022 | 2993 | 0.230 |
Why?
| | Hospitals, Urban | 5 | 2021 | 128 | 0.220 |
Why?
| | Injections, Intraperitoneal | 4 | 2009 | 97 | 0.220 |
Why?
| | Anti-Anxiety Agents | 2 | 2020 | 43 | 0.220 |
Why?
| | Animal Experimentation | 1 | 2003 | 5 | 0.220 |
Why?
| | Glasgow Coma Scale | 1 | 2004 | 148 | 0.220 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 230 | 0.210 |
Why?
| | Sensitivity and Specificity | 4 | 2010 | 1682 | 0.210 |
Why?
| | Calcium Chloride | 1 | 2003 | 14 | 0.210 |
Why?
| | Hospitals, Teaching | 3 | 2014 | 102 | 0.210 |
Why?
| | Magnesium Sulfate | 1 | 2003 | 16 | 0.210 |
Why?
| | Longevity | 3 | 2009 | 135 | 0.200 |
Why?
| | Cardiopulmonary Resuscitation | 3 | 2018 | 223 | 0.200 |
Why?
| | Logistic Models | 3 | 2017 | 1832 | 0.200 |
Why?
| | Umbilical Cord | 2 | 2021 | 80 | 0.200 |
Why?
| | Opiate Substitution Treatment | 2 | 2020 | 99 | 0.200 |
Why?
| | Placebos | 2 | 2014 | 198 | 0.200 |
Why?
| | Research Design | 3 | 2006 | 916 | 0.200 |
Why?
| | Desipramine | 1 | 2001 | 9 | 0.190 |
Why?
| | Severity of Illness Index | 1 | 2009 | 2530 | 0.190 |
Why?
| | Phenylurea Compounds | 1 | 2022 | 81 | 0.190 |
Why?
| | Hyperthermia, Induced | 1 | 2022 | 66 | 0.190 |
Why?
| | Narcotic Antagonists | 2 | 2020 | 135 | 0.190 |
Why?
| | Confidence Intervals | 4 | 2010 | 302 | 0.190 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 2021 | 21 | 0.180 |
Why?
| | Fractures, Bone | 2 | 2017 | 366 | 0.180 |
Why?
| | Heart Atria | 1 | 2001 | 107 | 0.180 |
Why?
| | Acute Disease | 2 | 2019 | 885 | 0.180 |
Why?
| | Mass Screening | 1 | 2007 | 978 | 0.170 |
Why?
| | Myocardial Contraction | 1 | 2001 | 314 | 0.170 |
Why?
| | Immunoglobulin Fragments | 1 | 1999 | 15 | 0.170 |
Why?
| | Lysergic Acid Diethylamide | 1 | 1999 | 2 | 0.170 |
Why?
| | Wisconsin | 1 | 2020 | 91 | 0.170 |
Why?
| | Droperidol | 1 | 1999 | 4 | 0.170 |
Why?
| | Lithium Carbonate | 1 | 1999 | 6 | 0.170 |
Why?
| | Serotonin Syndrome | 1 | 1999 | 5 | 0.170 |
Why?
| | Starch | 1 | 2019 | 20 | 0.170 |
Why?
| | Serotonin Receptor Agonists | 1 | 1999 | 27 | 0.170 |
Why?
| | Geriatric Assessment | 2 | 2011 | 175 | 0.170 |
Why?
| | Scorpion Stings | 1 | 1999 | 1 | 0.170 |
Why?
| | Nutritive Value | 1 | 2019 | 30 | 0.170 |
Why?
| | Community Health Workers | 1 | 2020 | 45 | 0.160 |
Why?
| | Administration, Oral | 4 | 2019 | 719 | 0.160 |
Why?
| | Ventricular Premature Complexes | 1 | 1999 | 26 | 0.160 |
Why?
| | Thrombocytopenia | 1 | 2021 | 175 | 0.160 |
Why?
| | Metabolome | 1 | 2022 | 275 | 0.160 |
Why?
| | Healthy Volunteers | 2 | 2019 | 186 | 0.160 |
Why?
| | Cannabidiol | 1 | 2020 | 60 | 0.160 |
Why?
| | Immune System | 1 | 2020 | 167 | 0.160 |
Why?
| | Cohort Studies | 7 | 2023 | 4880 | 0.160 |
Why?
| | Alcoholism | 3 | 2011 | 704 | 0.160 |
Why?
| | Fallopian Tube Diseases | 1 | 1998 | 5 | 0.160 |
Why?
| | Sex Factors | 5 | 2022 | 1705 | 0.160 |
Why?
| | Pregnancy, Tubal | 1 | 1998 | 5 | 0.160 |
Why?
| | Dietary Carbohydrates | 1 | 2019 | 137 | 0.160 |
Why?
| | Abortifacient Agents, Nonsteroidal | 1 | 1998 | 19 | 0.160 |
Why?
| | Munchausen Syndrome by Proxy | 1 | 1998 | 2 | 0.160 |
Why?
| | Plant Extracts | 1 | 2020 | 154 | 0.150 |
Why?
| | Snake Bites | 1 | 1999 | 54 | 0.150 |
Why?
| | Anticonvulsants | 1 | 2020 | 176 | 0.150 |
Why?
| | Faculty, Medical | 1 | 2021 | 226 | 0.150 |
Why?
| | Chi-Square Distribution | 2 | 2017 | 493 | 0.150 |
Why?
| | Genome-Wide Association Study | 2 | 2023 | 1157 | 0.150 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 224 | 0.150 |
Why?
| | Sulfasalazine | 1 | 1998 | 21 | 0.150 |
Why?
| | Drug Antagonism | 2 | 2009 | 8 | 0.150 |
Why?
| | Dyspnea | 1 | 1999 | 211 | 0.150 |
Why?
| | Drug Therapy, Combination | 3 | 2011 | 944 | 0.150 |
Why?
| | Survival Rate | 3 | 2013 | 1634 | 0.150 |
Why?
| | Incidence | 4 | 2013 | 2310 | 0.140 |
Why?
| | Drug Interactions | 4 | 2014 | 332 | 0.140 |
Why?
| | Out-of-Hospital Cardiac Arrest | 1 | 2018 | 78 | 0.140 |
Why?
| | Dietary Fats | 1 | 2019 | 286 | 0.140 |
Why?
| | Simulation Training | 1 | 2018 | 62 | 0.140 |
Why?
| | Methotrexate | 1 | 1998 | 227 | 0.140 |
Why?
| | Continuity of Patient Care | 1 | 2020 | 252 | 0.140 |
Why?
| | Gastrointestinal Agents | 1 | 1998 | 60 | 0.140 |
Why?
| | Peptide Fragments | 1 | 2021 | 652 | 0.140 |
Why?
| | Hypnotics and Sedatives | 1 | 1998 | 133 | 0.140 |
Why?
| | Mice | 7 | 2009 | 14679 | 0.140 |
Why?
| | Pain Management | 2 | 2017 | 285 | 0.140 |
Why?
| | Energy Intake | 1 | 2019 | 424 | 0.140 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 922 | 0.140 |
Why?
| | Ammonium Compounds | 1 | 2016 | 3 | 0.140 |
Why?
| | Prenatal Care | 1 | 2019 | 250 | 0.130 |
Why?
| | Fluorides | 1 | 2016 | 43 | 0.130 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 1783 | 0.130 |
Why?
| | Survival Analysis | 3 | 2010 | 1203 | 0.130 |
Why?
| | Cytochrome P-450 CYP2E1 Inhibitors | 1 | 2016 | 2 | 0.130 |
Why?
| | Metabolic Clearance Rate | 2 | 2019 | 103 | 0.130 |
Why?
| | Half-Life | 2 | 2019 | 140 | 0.130 |
Why?
| | Ventricular Fibrillation | 1 | 2016 | 51 | 0.130 |
Why?
| | Pilot Projects | 1 | 2020 | 1356 | 0.130 |
Why?
| | Pharmacovigilance | 1 | 2015 | 14 | 0.130 |
Why?
| | Genetic Variation | 1 | 2020 | 854 | 0.130 |
Why?
| | Calcium | 2 | 2016 | 1086 | 0.130 |
Why?
| | Herniorrhaphy | 1 | 2016 | 47 | 0.130 |
Why?
| | Milk | 1 | 2016 | 123 | 0.120 |
Why?
| | Models, Biological | 2 | 2015 | 1589 | 0.120 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2015 | 68 | 0.120 |
Why?
| | Fatal Outcome | 2 | 2013 | 280 | 0.120 |
Why?
| | Internship and Residency | 2 | 2014 | 920 | 0.120 |
Why?
| | Curriculum | 1 | 2021 | 803 | 0.120 |
Why?
| | Child Behavior | 1 | 2017 | 217 | 0.120 |
Why?
| | Hemodialysis Units, Hospital | 1 | 1994 | 5 | 0.120 |
Why?
| | Liver Failure, Acute | 1 | 2015 | 58 | 0.120 |
Why?
| | Ondansetron | 1 | 2014 | 8 | 0.120 |
Why?
| | Patient Simulation | 1 | 2014 | 29 | 0.120 |
Why?
| | Prognosis | 3 | 2011 | 3318 | 0.120 |
Why?
| | Physicians | 2 | 2020 | 765 | 0.120 |
Why?
| | Hydrocodone | 1 | 2014 | 15 | 0.120 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2014 | 24 | 0.120 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2015 | 79 | 0.120 |
Why?
| | Total Quality Management | 1 | 1994 | 61 | 0.120 |
Why?
| | Pregnancy Complications | 1 | 2019 | 427 | 0.110 |
Why?
| | Transaminases | 1 | 2014 | 24 | 0.110 |
Why?
| | Oxycodone | 1 | 2014 | 44 | 0.110 |
Why?
| | Acute Pain | 1 | 2014 | 35 | 0.110 |
Why?
| | Guanfacine | 1 | 2013 | 2 | 0.110 |
Why?
| | Remote Consultation | 1 | 2014 | 42 | 0.110 |
Why?
| | Walking | 1 | 2017 | 421 | 0.110 |
Why?
| | Vitamins | 1 | 2015 | 150 | 0.110 |
Why?
| | Clonidine | 1 | 2013 | 22 | 0.110 |
Why?
| | International Normalized Ratio | 2 | 2011 | 42 | 0.110 |
Why?
| | Indazoles | 1 | 2014 | 56 | 0.110 |
Why?
| | Cesium | 1 | 2013 | 16 | 0.110 |
Why?
| | Attitude of Health Personnel | 1 | 2020 | 970 | 0.110 |
Why?
| | Food | 1 | 2015 | 159 | 0.110 |
Why?
| | Pain Measurement | 4 | 2019 | 440 | 0.110 |
Why?
| | Deoxycholic Acid | 1 | 2013 | 15 | 0.110 |
Why?
| | Lethargy | 1 | 2012 | 4 | 0.100 |
Why?
| | Duloxetine Hydrochloride | 1 | 2012 | 8 | 0.100 |
Why?
| | Pyrazoles | 1 | 2016 | 361 | 0.100 |
Why?
| | Dabigatran | 1 | 2012 | 22 | 0.100 |
Why?
| | Marijuana Abuse | 1 | 2015 | 207 | 0.100 |
Why?
| | Sleep Stages | 1 | 2012 | 42 | 0.100 |
Why?
| | Chlorides | 1 | 2013 | 130 | 0.100 |
Why?
| | Tachycardia | 1 | 2012 | 50 | 0.100 |
Why?
| | Athletic Performance | 1 | 2013 | 54 | 0.100 |
Why?
| | Patient Discharge | 2 | 2016 | 770 | 0.100 |
Why?
| | Mycoses | 1 | 2013 | 66 | 0.100 |
Why?
| | Data Collection | 2 | 2013 | 616 | 0.100 |
Why?
| | Sulfhydryl Reagents | 1 | 2012 | 11 | 0.100 |
Why?
| | Dizziness | 1 | 2012 | 70 | 0.100 |
Why?
| | Accidental Falls | 2 | 2011 | 150 | 0.100 |
Why?
| | Follow-Up Studies | 3 | 2010 | 4384 | 0.100 |
Why?
| | Arsenicals | 1 | 2012 | 24 | 0.100 |
Why?
| | Drug Combinations | 1 | 2013 | 285 | 0.100 |
Why?
| | Sampling Studies | 1 | 2012 | 90 | 0.100 |
Why?
| | Laparoscopy | 1 | 2016 | 393 | 0.100 |
Why?
| | Information Systems | 1 | 2011 | 61 | 0.090 |
Why?
| | Sulfides | 1 | 2012 | 92 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2015 | 223 | 0.090 |
Why?
| | Dietary Supplements | 1 | 2015 | 459 | 0.090 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 497 | 0.090 |
Why?
| | Arabia | 1 | 2011 | 2 | 0.090 |
Why?
| | Hepatic Encephalopathy | 1 | 2011 | 19 | 0.090 |
Why?
| | Immunocompromised Host | 1 | 2013 | 190 | 0.090 |
Why?
| | Levamisole | 1 | 2011 | 20 | 0.090 |
Why?
| | Molecular Structure | 1 | 2012 | 429 | 0.090 |
Why?
| | Drug Contamination | 1 | 2011 | 52 | 0.090 |
Why?
| | Sports | 1 | 2013 | 187 | 0.090 |
Why?
| | Universities | 1 | 2013 | 337 | 0.090 |
Why?
| | Pharmacogenetics | 1 | 2012 | 149 | 0.090 |
Why?
| | Glipizide | 1 | 2010 | 6 | 0.090 |
Why?
| | Laboratories, Hospital | 1 | 2010 | 14 | 0.090 |
Why?
| | Hepatitis, Alcoholic | 1 | 2010 | 13 | 0.090 |
Why?
| | Troponin | 1 | 2010 | 44 | 0.090 |
Why?
| | Drug Prescriptions | 2 | 2016 | 237 | 0.090 |
Why?
| | Glyburide | 1 | 2010 | 34 | 0.090 |
Why?
| | Crowding | 1 | 2010 | 36 | 0.080 |
Why?
| | Body Weight | 1 | 2014 | 853 | 0.080 |
Why?
| | Watchful Waiting | 1 | 2010 | 54 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2011 | 204 | 0.080 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2011 | 156 | 0.080 |
Why?
| | Health Services Accessibility | 1 | 2015 | 756 | 0.080 |
Why?
| | Quetiapine Fumarate | 1 | 2009 | 20 | 0.080 |
Why?
| | Dibenzothiazepines | 1 | 2009 | 17 | 0.080 |
Why?
| | Aripiprazole | 1 | 2009 | 16 | 0.080 |
Why?
| | Dogs | 1 | 2010 | 325 | 0.080 |
Why?
| | Risperidone | 1 | 2009 | 26 | 0.080 |
Why?
| | Potassium | 1 | 2009 | 127 | 0.080 |
Why?
| | Renal Dialysis | 1 | 2013 | 377 | 0.080 |
Why?
| | Glutathione | 3 | 2022 | 291 | 0.080 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 126 | 0.080 |
Why?
| | Head Protective Devices | 1 | 2009 | 14 | 0.080 |
Why?
| | Role | 1 | 2009 | 32 | 0.080 |
Why?
| | Body Temperature | 1 | 2009 | 176 | 0.080 |
Why?
| | Workload | 1 | 2010 | 131 | 0.080 |
Why?
| | Quality Control | 1 | 2009 | 142 | 0.080 |
Why?
| | Bibliometrics | 1 | 2009 | 43 | 0.080 |
Why?
| | Acidosis | 2 | 2006 | 85 | 0.080 |
Why?
| | Diarrhea | 1 | 2009 | 170 | 0.080 |
Why?
| | Quality Indicators, Health Care | 1 | 2011 | 285 | 0.080 |
Why?
| | Students | 1 | 2013 | 491 | 0.080 |
Why?
| | Skiing | 1 | 2009 | 42 | 0.080 |
Why?
| | Informed Consent | 2 | 2006 | 158 | 0.080 |
Why?
| | Pharmacy Service, Hospital | 1 | 2009 | 83 | 0.080 |
Why?
| | Cause of Death | 1 | 2010 | 360 | 0.070 |
Why?
| | Acetone | 1 | 2008 | 10 | 0.070 |
Why?
| | Hair Preparations | 1 | 2008 | 2 | 0.070 |
Why?
| | Bacitracin | 1 | 2008 | 6 | 0.070 |
Why?
| | Adhesiveness | 1 | 2008 | 19 | 0.070 |
Why?
| | Nylons | 1 | 2008 | 18 | 0.070 |
Why?
| | Quinolones | 1 | 2009 | 97 | 0.070 |
Why?
| | Propylene Glycols | 1 | 2008 | 25 | 0.070 |
Why?
| | Withholding Treatment | 1 | 2008 | 66 | 0.070 |
Why?
| | Substance Abuse Detection | 2 | 2021 | 62 | 0.070 |
Why?
| | Equipment Design | 1 | 2009 | 496 | 0.070 |
Why?
| | Drug Synergism | 1 | 2008 | 312 | 0.070 |
Why?
| | Glycerol | 1 | 2008 | 84 | 0.070 |
Why?
| | Cellulose | 1 | 2008 | 57 | 0.070 |
Why?
| | Hospitalization | 2 | 2011 | 1765 | 0.070 |
Why?
| | Nephelometry and Turbidimetry | 1 | 2007 | 15 | 0.070 |
Why?
| | Military Personnel | 1 | 2014 | 522 | 0.070 |
Why?
| | Laboratories | 1 | 2008 | 95 | 0.070 |
Why?
| | Polypharmacy | 1 | 2008 | 74 | 0.070 |
Why?
| | Tissue Distribution | 2 | 2019 | 280 | 0.070 |
Why?
| | Kidney Transplantation | 1 | 2013 | 537 | 0.070 |
Why?
| | Research | 2 | 2011 | 387 | 0.070 |
Why?
| | Phosphates | 1 | 2008 | 154 | 0.070 |
Why?
| | Periodicals as Topic | 1 | 2009 | 180 | 0.070 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1114 | 0.070 |
Why?
| | Formates | 1 | 2006 | 12 | 0.070 |
Why?
| | Aging | 2 | 2014 | 1601 | 0.070 |
Why?
| | Methanol | 1 | 2006 | 29 | 0.070 |
Why?
| | Defibrillators | 1 | 2006 | 16 | 0.070 |
Why?
| | Blindness | 1 | 2006 | 36 | 0.070 |
Why?
| | Vasopressins | 1 | 2006 | 56 | 0.070 |
Why?
| | Statistics, Nonparametric | 1 | 2007 | 384 | 0.070 |
Why?
| | Telemedicine | 1 | 2014 | 666 | 0.070 |
Why?
| | Respiratory Insufficiency | 1 | 2009 | 285 | 0.070 |
Why?
| | Probability | 2 | 2010 | 285 | 0.070 |
Why?
| | Naproxen | 1 | 2006 | 11 | 0.060 |
Why?
| | Spinal Diseases | 1 | 2006 | 39 | 0.060 |
Why?
| | Health Services for the Aged | 1 | 2006 | 70 | 0.060 |
Why?
| | Population Dynamics | 1 | 2006 | 122 | 0.060 |
Why?
| | Ipecac | 1 | 2005 | 8 | 0.060 |
Why?
| | Respiration, Artificial | 1 | 2009 | 536 | 0.060 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1378 | 0.060 |
Why?
| | Geriatrics | 1 | 2006 | 69 | 0.060 |
Why?
| | Epinephrine | 1 | 2006 | 160 | 0.060 |
Why?
| | Ibuprofen | 1 | 2006 | 75 | 0.060 |
Why?
| | Hospitals, University | 1 | 2006 | 169 | 0.060 |
Why?
| | Haplorhini | 1 | 2005 | 56 | 0.060 |
Why?
| | Premedication | 1 | 2005 | 36 | 0.060 |
Why?
| | Blood Glucose | 2 | 2019 | 1823 | 0.060 |
Why?
| | Motivation | 1 | 2009 | 486 | 0.060 |
Why?
| | Spine | 1 | 2006 | 136 | 0.060 |
Why?
| | Risk | 1 | 2007 | 807 | 0.060 |
Why?
| | Water | 1 | 2008 | 394 | 0.060 |
Why?
| | Single-Blind Method | 1 | 2005 | 255 | 0.060 |
Why?
| | Fluoride Poisoning | 1 | 2004 | 4 | 0.060 |
Why?
| | Resuscitation | 1 | 2006 | 221 | 0.060 |
Why?
| | Pregnancy | 3 | 2021 | 5490 | 0.060 |
Why?
| | Guidelines as Topic | 1 | 2005 | 241 | 0.060 |
Why?
| | Health Policy | 1 | 2006 | 330 | 0.050 |
Why?
| | Maltose | 1 | 2023 | 5 | 0.050 |
Why?
| | Hydroxyzine | 1 | 2023 | 3 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2004 | 75 | 0.050 |
Why?
| | Magnesium | 1 | 2004 | 144 | 0.050 |
Why?
| | Sheep | 1 | 2006 | 760 | 0.050 |
Why?
| | Aspirin | 1 | 2006 | 325 | 0.050 |
Why?
| | Patient Participation | 1 | 2006 | 348 | 0.050 |
Why?
| | Urea | 1 | 2023 | 65 | 0.050 |
Why?
| | Survival | 1 | 2003 | 37 | 0.050 |
Why?
| | Prevalence | 3 | 2015 | 2244 | 0.050 |
Why?
| | Internet | 1 | 2007 | 590 | 0.050 |
Why?
| | Urban Population | 2 | 2019 | 393 | 0.050 |
Why?
| | Canada | 1 | 2023 | 320 | 0.050 |
Why?
| | Lactates | 1 | 2022 | 77 | 0.050 |
Why?
| | Sex Distribution | 2 | 2015 | 336 | 0.050 |
Why?
| | Breast Neoplasms | 1 | 2013 | 1842 | 0.050 |
Why?
| | Culture Techniques | 1 | 2001 | 76 | 0.050 |
Why?
| | Academic Medical Centers | 2 | 2016 | 406 | 0.050 |
Why?
| | Blood Physiological Phenomena | 1 | 2021 | 13 | 0.050 |
Why?
| | Neural Conduction | 1 | 2001 | 78 | 0.050 |
Why?
| | Hirudins | 1 | 2021 | 46 | 0.050 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2020 | 27 | 0.040 |
Why?
| | Infusions, Parenteral | 1 | 2020 | 36 | 0.040 |
Why?
| | Certification | 1 | 2020 | 84 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2004 | 633 | 0.040 |
Why?
| | Pirenzepine | 1 | 1999 | 7 | 0.040 |
Why?
| | Temperature | 1 | 2022 | 557 | 0.040 |
Why?
| | Scorpions | 1 | 1999 | 2 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 480 | 0.040 |
Why?
| | South America | 1 | 1999 | 52 | 0.040 |
Why?
| | Blood Cell Count | 2 | 2013 | 50 | 0.040 |
Why?
| | Narcotics | 1 | 1999 | 44 | 0.040 |
Why?
| | Postprandial Period | 1 | 2019 | 86 | 0.040 |
Why?
| | Biological Availability | 1 | 2019 | 119 | 0.040 |
Why?
| | Rupture, Spontaneous | 1 | 1998 | 16 | 0.040 |
Why?
| | Manikins | 1 | 2018 | 23 | 0.040 |
Why?
| | Central Nervous System Depressants | 1 | 1999 | 80 | 0.040 |
Why?
| | Videotape Recording | 1 | 2018 | 30 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2001 | 1208 | 0.040 |
Why?
| | Lipids | 1 | 2022 | 558 | 0.040 |
Why?
| | Sorption Detoxification | 1 | 1998 | 3 | 0.040 |
Why?
| | Dietary Proteins | 1 | 2019 | 121 | 0.040 |
Why?
| | North America | 1 | 1999 | 256 | 0.040 |
Why?
| | Cholinesterase Inhibitors | 1 | 1998 | 26 | 0.040 |
Why?
| | Laparotomy | 1 | 1998 | 101 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2021 | 1214 | 0.040 |
Why?
| | Feedback | 1 | 2018 | 141 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2019 | 432 | 0.040 |
Why?
| | Maternal Health Services | 1 | 2019 | 79 | 0.040 |
Why?
| | Central Nervous System | 1 | 1999 | 229 | 0.040 |
Why?
| | Triglycerides | 1 | 2019 | 464 | 0.040 |
Why?
| | Socioeconomic Factors | 2 | 2015 | 1080 | 0.040 |
Why?
| | Registries | 2 | 2010 | 1762 | 0.040 |
Why?
| | Bipolar Disorder | 1 | 1999 | 200 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 912 | 0.030 |
Why?
| | Hallucinogens | 1 | 2017 | 72 | 0.030 |
Why?
| | Dialysis | 1 | 2015 | 18 | 0.030 |
Why?
| | Centrifugation | 1 | 2015 | 28 | 0.030 |
Why?
| | Verapamil | 1 | 2014 | 32 | 0.030 |
Why?
| | Tennessee | 1 | 1994 | 42 | 0.030 |
Why?
| | Observation | 1 | 2014 | 50 | 0.030 |
Why?
| | Protein Binding | 1 | 2020 | 1867 | 0.030 |
Why?
| | Hematocrit | 1 | 1994 | 88 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2015 | 115 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 821 | 0.030 |
Why?
| | Syndrome | 1 | 2015 | 328 | 0.030 |
Why?
| | Anesthetics, Local | 1 | 2014 | 81 | 0.030 |
Why?
| | Erythropoietin | 1 | 1994 | 69 | 0.030 |
Why?
| | Warfare | 1 | 2014 | 74 | 0.030 |
Why?
| | Injections, Intralesional | 1 | 2013 | 32 | 0.030 |
Why?
| | Hospitals, Veterans | 1 | 1994 | 244 | 0.030 |
Why?
| | Salicylates | 1 | 2013 | 30 | 0.030 |
Why?
| | Iron | 1 | 1994 | 232 | 0.030 |
Why?
| | Urinalysis | 1 | 2013 | 65 | 0.030 |
Why?
| | Nursing Staff, Hospital | 1 | 1994 | 123 | 0.030 |
Why?
| | Hemoglobins | 1 | 1994 | 303 | 0.030 |
Why?
| | Long QT Syndrome | 1 | 2013 | 59 | 0.030 |
Why?
| | Therapeutic Irrigation | 1 | 2012 | 64 | 0.020 |
Why?
| | Receptors, Opioid, mu | 1 | 2012 | 50 | 0.020 |
Why?
| | Computer Simulation | 1 | 2015 | 858 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2019 | 1068 | 0.020 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2012 | 108 | 0.020 |
Why?
| | Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2011 | 6 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2011 | 48 | 0.020 |
Why?
| | Agranulocytosis | 1 | 2011 | 31 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2014 | 305 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2012 | 123 | 0.020 |
Why?
| | Leukoencephalopathies | 1 | 2011 | 21 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2015 | 572 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2011 | 118 | 0.020 |
Why?
| | Toothache | 1 | 2010 | 5 | 0.020 |
Why?
| | Models, Theoretical | 1 | 1994 | 505 | 0.020 |
Why?
| | Immunoassay | 1 | 2011 | 94 | 0.020 |
Why?
| | Insurance Coverage | 1 | 2012 | 199 | 0.020 |
Why?
| | Drug Administration Routes | 1 | 2010 | 38 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 1994 | 665 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2010 | 195 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2010 | 111 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 1994 | 490 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 341 | 0.020 |
Why?
| | Intestines | 1 | 2012 | 324 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 603 | 0.020 |
Why?
| | Precision Medicine | 1 | 2012 | 335 | 0.020 |
Why?
| | Safety | 1 | 2010 | 297 | 0.020 |
Why?
| | Clinical Competence | 1 | 2014 | 882 | 0.020 |
Why?
| | Ethanol | 1 | 2012 | 532 | 0.020 |
Why?
| | Seasons | 1 | 2010 | 437 | 0.020 |
Why?
| | Triage | 1 | 2010 | 197 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 932 | 0.020 |
Why?
| | Disease Management | 1 | 2011 | 554 | 0.020 |
Why?
| | Metabolomics | 1 | 2012 | 508 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 1733 | 0.020 |
Why?
| | Bilirubin | 1 | 2007 | 88 | 0.020 |
Why?
| | Pulse | 1 | 2006 | 25 | 0.020 |
Why?
| | Blastomycosis | 1 | 2006 | 8 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2007 | 5032 | 0.020 |
Why?
| | Contraindications | 1 | 2006 | 84 | 0.020 |
Why?
| | Amyloidosis | 1 | 2006 | 36 | 0.020 |
Why?
| | Coronary Circulation | 1 | 2006 | 131 | 0.020 |
Why?
| | Biopsy, Fine-Needle | 1 | 2006 | 65 | 0.020 |
Why?
| | Electric Countershock | 1 | 2006 | 104 | 0.020 |
Why?
| | European Union | 1 | 2005 | 8 | 0.020 |
Why?
| | Fever | 1 | 2007 | 266 | 0.020 |
Why?
| | Disaster Planning | 1 | 2006 | 74 | 0.020 |
Why?
| | Emergencies | 1 | 2006 | 144 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2006 | 633 | 0.010 |
Why?
| | United States Food and Drug Administration | 1 | 2005 | 172 | 0.010 |
Why?
| | Up-Regulation | 1 | 2007 | 794 | 0.010 |
Why?
| | Renal Insufficiency | 1 | 2006 | 138 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 2754 | 0.010 |
Why?
| | Swine | 1 | 2006 | 687 | 0.010 |
Why?
| | Pharmaceutical Preparations | 1 | 2006 | 163 | 0.010 |
Why?
| | Brain Injuries | 1 | 2009 | 449 | 0.010 |
Why?
| | Mice, Inbred ICR | 1 | 2004 | 108 | 0.010 |
Why?
| | Lupus Nephritis | 1 | 2004 | 52 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2004 | 996 | 0.010 |
Why?
| | Blood Pressure | 1 | 2006 | 1521 | 0.010 |
Why?
| | Miosis | 1 | 1999 | 3 | 0.010 |
Why?
| | Pupil | 1 | 1999 | 13 | 0.010 |
Why?
| | Hemodynamics | 1 | 2004 | 996 | 0.010 |
Why?
| | Chronic Disease | 1 | 2004 | 1570 | 0.010 |
Why?
| | Algorithms | 1 | 2004 | 1462 | 0.010 |
Why?
| | Neoplasms | 1 | 2006 | 2082 | 0.010 |
Why?
|
|
Heard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|